Massachusetts Society of Clinical Oncologists - FDA Approval for Expanded Use of ibrutinib (imbruvica)

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA Approval for Expanded Use of ibrutinib (imbruvica)

FDA Approval for Expanded Use of ibrutinib (imbruvica)

05 Feb 2019 1:50 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved the expanded use of ibrutinib (imbruvica; Pharmacyclics) in combination with obinutuzumab for adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org